Laboratory Services
SARS CoV 2 Nucleocapsid Antibody, IgG
Print this pageUpdated Test Information:
| Test Description |
SARS CoV 2 Nucleocapsid Antibody, IgG
|
|
|---|---|---|
| Synonym(s) |
2019-nCoV, antibody, corona, coronavirus, COVID, COVID-19, COVID19, IgG, nCoV, SARS, SARS-CoV-2, UOW3785 |
|
| Test ID |
NCVIGG
|
|
| General Information |
The Abbott Architect SARS-CoV-2 IgG assay, run under an emergency use authorization from the FDA, is a qualitative test designed to detect IgG antibodies to the nucleocapsid protein of SARS-CoV-2 in serum and plasma from patients who are suspected of past coronavirus disease (COVID-19) or in serum and plasma of subjects that may have been infected by SARS-CoV-2. |
|
| Container Type |
5 mL blood in GOLD SST tube |
|
| Specimen Type |
Serum |
|
| Alternate Specimen Type |
Orange RST, pearl PPT, serum from red top, plasma from EDTA tube |
|
| Specimen Collection / Processing Instructions |
Centrifuge GOLD SST tube. Centrifuge RED TOP or EDTA tube and aliquot serum/plasma into plastic aliquot tube. |
|
| Minimum Sample Volume |
0.5 mL |
|
| Additional Processing Details |
Spin within 24 hours and prior to shipment. Sample is stable for 7 days at 2-8°C once separated from a clot or red blood cells, or in a gel separator tube. If testing will be delayed more than 7 days store at -20°C or colder. |
|
| Stability |
Sample stable off the clot, red blood cells, or separator gel for 7 days at 2-8°C. If testing will be delayed more than 7 days store at -20°C or colder. |
|
| Methodology |
Chemiluminesence |
|
| Estimated TAT |
2 days |
|
| Testing Schedule |
Monday-Sunday |
|
| CPT Code(s) |
86769 |
|
| Reference Range |
Reactive (Positive) results may be due to past or present infection with SARS-CoV-2. Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status. Nonreactive (Negative) results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Follow-up testing with a molecular diagnostic should be considered to rule out infection in these individuals. Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status. This test run under an emergency use authorization from the FDA. |
|
| STAT Orderable (Y/N) |
No |
|
| Performing Lab |
UW |
|
| LOINC Code(s) |
94504-8 |
|
| Additional Information |
The COVID-19 antibody assay is for in vitro diagnostic use under an FDA Emergency Use Authorization (EUA). |
